Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers
Само за регистроване кориснике
2013
Аутори
Karan-Đurašević, TeodoraPalibrk, Vuk
Zukić, Branka
Spasovski, Vesna
Marjanović, Irena
Colović, Milica
Čolović, Nataša
Jurisić, Vladimir
Scorilas, Andreas
Pavlović, Sonja
Tošić, Nataša
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Dysregulation of apoptosis is a distinctive feature of chronic lymphocytic leukemia (CLL), although a unique mechanism underlying apoptosis resistance of CLL B lymphocytes has not been identified yet. Aberrant expression as well as genetic and epigenetic alterations of numerous genes involved in different pathways of apoptosis regulation has been described in CLL. Here, we report the expression analysis of Bcl2L12 (Bcl2-like 12), a novel apoptotic gene belonging to Bcl2 family, in 58 Serbian CLL patients. Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) analysis revealed a significant overexpression of Bcl2L12 mRNA in CLL samples compared to non-leukemic samples, implying its role in the pathogenesis of the disease. Receiver operating characteristic (ROC) analysis showed that Bcl2L12 expression efficiently discriminates CLL cases from healthy controls. However, relatively homogenous Bcl2L12 mRNA expression among patients did not reflect their clinical characterist...ics (with the exception of lactate dehydrogenase status and time from diagnosis to treatment) and failed to show association with the most informative prognostic markers, namely the mutational status of rearranged immunoglobulin heavy chain variable region genes, CD38 and lipoprotein lipase gene (LPL) expression.
Кључне речи:
LPL / IGHV mutational status / Expression analysis / Chronic lymphocytic leukemia / CD38 / Bcl2L12Извор:
Medical Oncology, 2013, 30, 1Издавач:
- Humana Press Inc, Totowa
Финансирање / пројекти:
- Ретке болести: молекуларна патофизиологија, дијагностички и терапијски модалитети и социјални, етички и правни аспекти (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41004)
- Молекулске, биохемијске и имунолошке анализе у дијагностици тумора (RS-MESTD-Basic Research (BR or ON)-175056)
DOI: 10.1007/s12032-012-0405-7
ISSN: 1357-0560
PubMed: 23292833
WoS: 000316800800083
Scopus: 2-s2.0-84871720560
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Karan-Đurašević, Teodora AU - Palibrk, Vuk AU - Zukić, Branka AU - Spasovski, Vesna AU - Marjanović, Irena AU - Colović, Milica AU - Čolović, Nataša AU - Jurisić, Vladimir AU - Scorilas, Andreas AU - Pavlović, Sonja AU - Tošić, Nataša PY - 2013 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/641 AB - Dysregulation of apoptosis is a distinctive feature of chronic lymphocytic leukemia (CLL), although a unique mechanism underlying apoptosis resistance of CLL B lymphocytes has not been identified yet. Aberrant expression as well as genetic and epigenetic alterations of numerous genes involved in different pathways of apoptosis regulation has been described in CLL. Here, we report the expression analysis of Bcl2L12 (Bcl2-like 12), a novel apoptotic gene belonging to Bcl2 family, in 58 Serbian CLL patients. Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) analysis revealed a significant overexpression of Bcl2L12 mRNA in CLL samples compared to non-leukemic samples, implying its role in the pathogenesis of the disease. Receiver operating characteristic (ROC) analysis showed that Bcl2L12 expression efficiently discriminates CLL cases from healthy controls. However, relatively homogenous Bcl2L12 mRNA expression among patients did not reflect their clinical characteristics (with the exception of lactate dehydrogenase status and time from diagnosis to treatment) and failed to show association with the most informative prognostic markers, namely the mutational status of rearranged immunoglobulin heavy chain variable region genes, CD38 and lipoprotein lipase gene (LPL) expression. PB - Humana Press Inc, Totowa T2 - Medical Oncology T1 - Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers IS - 1 VL - 30 DO - 10.1007/s12032-012-0405-7 ER -
@article{ author = "Karan-Đurašević, Teodora and Palibrk, Vuk and Zukić, Branka and Spasovski, Vesna and Marjanović, Irena and Colović, Milica and Čolović, Nataša and Jurisić, Vladimir and Scorilas, Andreas and Pavlović, Sonja and Tošić, Nataša", year = "2013", abstract = "Dysregulation of apoptosis is a distinctive feature of chronic lymphocytic leukemia (CLL), although a unique mechanism underlying apoptosis resistance of CLL B lymphocytes has not been identified yet. Aberrant expression as well as genetic and epigenetic alterations of numerous genes involved in different pathways of apoptosis regulation has been described in CLL. Here, we report the expression analysis of Bcl2L12 (Bcl2-like 12), a novel apoptotic gene belonging to Bcl2 family, in 58 Serbian CLL patients. Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) analysis revealed a significant overexpression of Bcl2L12 mRNA in CLL samples compared to non-leukemic samples, implying its role in the pathogenesis of the disease. Receiver operating characteristic (ROC) analysis showed that Bcl2L12 expression efficiently discriminates CLL cases from healthy controls. However, relatively homogenous Bcl2L12 mRNA expression among patients did not reflect their clinical characteristics (with the exception of lactate dehydrogenase status and time from diagnosis to treatment) and failed to show association with the most informative prognostic markers, namely the mutational status of rearranged immunoglobulin heavy chain variable region genes, CD38 and lipoprotein lipase gene (LPL) expression.", publisher = "Humana Press Inc, Totowa", journal = "Medical Oncology", title = "Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers", number = "1", volume = "30", doi = "10.1007/s12032-012-0405-7" }
Karan-Đurašević, T., Palibrk, V., Zukić, B., Spasovski, V., Marjanović, I., Colović, M., Čolović, N., Jurisić, V., Scorilas, A., Pavlović, S.,& Tošić, N.. (2013). Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers. in Medical Oncology Humana Press Inc, Totowa., 30(1). https://doi.org/10.1007/s12032-012-0405-7
Karan-Đurašević T, Palibrk V, Zukić B, Spasovski V, Marjanović I, Colović M, Čolović N, Jurisić V, Scorilas A, Pavlović S, Tošić N. Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers. in Medical Oncology. 2013;30(1). doi:10.1007/s12032-012-0405-7 .
Karan-Đurašević, Teodora, Palibrk, Vuk, Zukić, Branka, Spasovski, Vesna, Marjanović, Irena, Colović, Milica, Čolović, Nataša, Jurisić, Vladimir, Scorilas, Andreas, Pavlović, Sonja, Tošić, Nataša, "Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers" in Medical Oncology, 30, no. 1 (2013), https://doi.org/10.1007/s12032-012-0405-7 . .